Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 198, Issue 2, Pages 328-332Publisher
WILEY
DOI: 10.1111/bjh.18216
Keywords
amyloidosis; multiple myeloma; MGUS
Categories
Ask authors/readers for more resources
This study found that depth of response is critical in the prognosis of AL amyloidosis. By analyzing patients' baseline characteristics and 1-month response, those unlikely to improve treatment response can be identified. It is recommended that patients with a significant difference in involved and uninvolved serum free light chains at diagnosis and no response at 1 month switch treatment early.
Depth of response is the critical determinant of prognosis in amyloid light-chain (AL) amyloidosis. Here, we aim to identify patients who are unlikely to improve response based on analysis of baseline characteristics and 1-month response. In a multivariate model, difference in involved amyloidogenic and uninvolved serum free light chains (dFLC) at diagnosis (dFLC >400 mg/l, odds ratio [OR] 4.051, p < 0.005) and no response at 1 month (OR 4.787, p < 0.005) were significant predictors of no improvement in response. Only 5% of patients with a dFLC of >400 mg/l and no response at 1 month improved their response (p < 0.005). We suggest that these patients should switch treatment early, subject to their functional status.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available